AlphaRx Inc.: AlphaRx Provides Update on Phase II Trial of Indaflex(TM) for the Treatment of Osteoarthritis of the Knee
12th Sep 2005, 14:47 GMT
MARKHAM, ON (MARKET WIRE) AlphaRx Inc. (OTC BB: ALRX), an emerging biopharmaceutical company, utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to provided an update on the clinical development of its lead product candidate Indaflex(TM), a topical Indomethacin drug expected to treat patients suffering from Osteoarthritis of the knee.
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech